| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis | 73 | 2025 | 543 | 13.580 |
Why?
|
| HIV Infections | 176 | 2024 | 5097 | 11.690 |
Why?
|
| Tuberculosis, Pulmonary | 40 | 2024 | 324 | 7.670 |
Why?
|
| Mycobacterium tuberculosis | 37 | 2024 | 329 | 6.800 |
Why?
|
| Humans | 276 | 2025 | 14537 | 5.390 |
Why?
|
| Antitubercular Agents | 38 | 2024 | 322 | 5.250 |
Why?
|
| South Africa | 195 | 2025 | 7596 | 5.190 |
Why?
|
| Adult | 175 | 2024 | 5913 | 5.100 |
Why?
|
| Male | 154 | 2025 | 6754 | 4.580 |
Why?
|
| Circumcision, Male | 19 | 2024 | 99 | 4.450 |
Why?
|
| Female | 171 | 2025 | 9103 | 4.350 |
Why?
|
| Latent Tuberculosis | 14 | 2023 | 45 | 3.900 |
Why?
|
| Isoniazid | 20 | 2024 | 110 | 3.830 |
Why?
|
| AIDS-Related Opportunistic Infections | 16 | 2021 | 195 | 3.640 |
Why?
|
| Contact Tracing | 12 | 2023 | 48 | 3.310 |
Why?
|
| HIV-1 | 35 | 2024 | 1260 | 2.850 |
Why?
|
| CD4 Lymphocyte Count | 35 | 2024 | 656 | 2.800 |
Why?
|
| Middle Aged | 80 | 2024 | 3601 | 2.670 |
Why?
|
| Anti-HIV Agents | 37 | 2024 | 1324 | 2.650 |
Why?
|
| Young Adult | 65 | 2024 | 2498 | 2.480 |
Why?
|
| Sputum | 17 | 2023 | 135 | 2.420 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 11 | 2024 | 226 | 2.230 |
Why?
|
| Antiretroviral Therapy, Highly Active | 16 | 2017 | 472 | 2.120 |
Why?
|
| Hospitalization | 13 | 2024 | 418 | 2.100 |
Why?
|
| Rifampin | 15 | 2023 | 197 | 2.090 |
Why?
|
| Prospective Studies | 42 | 2025 | 1160 | 2.080 |
Why?
|
| Pregnancy Complications, Infectious | 18 | 2020 | 529 | 1.950 |
Why?
|
| Cross-Sectional Studies | 44 | 2023 | 1422 | 1.940 |
Why?
|
| Adolescent | 55 | 2024 | 2985 | 1.870 |
Why?
|
| Anti-Retroviral Agents | 12 | 2024 | 551 | 1.860 |
Why?
|
| Family Characteristics | 18 | 2023 | 135 | 1.840 |
Why?
|
| HIV | 14 | 2023 | 380 | 1.830 |
Why?
|
| Coinfection | 12 | 2022 | 276 | 1.670 |
Why?
|
| Patient Acceptance of Health Care | 13 | 2023 | 256 | 1.670 |
Why?
|
| Viral Load | 22 | 2022 | 819 | 1.660 |
Why?
|
| Infectious Disease Transmission, Vertical | 16 | 2019 | 472 | 1.630 |
Why?
|
| Prevalence | 32 | 2023 | 1192 | 1.560 |
Why?
|
| Sexual Behavior | 8 | 2019 | 320 | 1.560 |
Why?
|
| Tuberculin Test | 11 | 2020 | 49 | 1.470 |
Why?
|
| Nevirapine | 14 | 2017 | 146 | 1.450 |
Why?
|
| Pre-Exposure Prophylaxis | 9 | 2024 | 196 | 1.420 |
Why?
|
| Child | 33 | 2024 | 2242 | 1.400 |
Why?
|
| HIV Seropositivity | 7 | 2023 | 265 | 1.300 |
Why?
|
| Treatment Outcome | 19 | 2024 | 889 | 1.280 |
Why?
|
| Risk Factors | 24 | 2024 | 1475 | 1.250 |
Why?
|
| Aged | 28 | 2024 | 1740 | 1.170 |
Why?
|
| Primary Health Care | 10 | 2023 | 240 | 1.140 |
Why?
|
| Pregnancy | 30 | 2022 | 1862 | 1.130 |
Why?
|
| Ambulatory Care Facilities | 9 | 2022 | 125 | 1.120 |
Why?
|
| Influenza, Human | 9 | 2025 | 374 | 1.120 |
Why?
|
| Infant | 26 | 2025 | 2244 | 1.080 |
Why?
|
| Communicable Disease Control | 4 | 2023 | 101 | 1.070 |
Why?
|
| Incidence | 15 | 2025 | 685 | 1.060 |
Why?
|
| Disease Notification | 3 | 2025 | 14 | 1.040 |
Why?
|
| Bacteriological Techniques | 5 | 2021 | 54 | 1.030 |
Why?
|
| Mass Screening | 13 | 2023 | 245 | 1.010 |
Why?
|
| Surgical Instruments | 3 | 2019 | 11 | 1.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 8 | 2023 | 262 | 1.000 |
Why?
|
| Drug Resistance, Viral | 10 | 2016 | 278 | 0.990 |
Why?
|
| Cell Phone | 3 | 2020 | 34 | 0.980 |
Why?
|
| Cohort Studies | 25 | 2024 | 967 | 0.940 |
Why?
|
| Foreskin | 4 | 2024 | 12 | 0.940 |
Why?
|
| Child, Preschool | 21 | 2024 | 1748 | 0.920 |
Why?
|
| Surveys and Questionnaires | 15 | 2018 | 563 | 0.880 |
Why?
|
| Home Care Services | 1 | 2024 | 15 | 0.870 |
Why?
|
| Infant, Newborn | 17 | 2022 | 1479 | 0.870 |
Why?
|
| Levofloxacin | 5 | 2024 | 21 | 0.870 |
Why?
|
| Exhalation | 1 | 2023 | 3 | 0.840 |
Why?
|
| Community-Acquired Infections | 1 | 2024 | 102 | 0.840 |
Why?
|
| Smoking Cessation | 4 | 2024 | 9 | 0.830 |
Why?
|
| Cervical Intraepithelial Neoplasia | 4 | 2014 | 36 | 0.820 |
Why?
|
| Drug Therapy, Combination | 12 | 2024 | 279 | 0.810 |
Why?
|
| Rifamycins | 1 | 2022 | 1 | 0.800 |
Why?
|
| Sensitivity and Specificity | 13 | 2023 | 385 | 0.790 |
Why?
|
| Point-of-Care Systems | 1 | 2023 | 91 | 0.790 |
Why?
|
| Tobacco Use Disorder | 1 | 2022 | 7 | 0.790 |
Why?
|
| Cannabis | 1 | 2022 | 10 | 0.790 |
Why?
|
| Tobacco Smoking | 2 | 2022 | 15 | 0.780 |
Why?
|
| Pneumococcal Vaccines | 2 | 2024 | 278 | 0.780 |
Why?
|
| Drug Administration Schedule | 12 | 2022 | 156 | 0.770 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2014 | 115 | 0.770 |
Why?
|
| Bacterial Load | 2 | 2023 | 32 | 0.760 |
Why?
|
| Predictive Value of Tests | 8 | 2021 | 188 | 0.760 |
Why?
|
| Lung | 5 | 2023 | 70 | 0.750 |
Why?
|
| Rural Population | 11 | 2021 | 654 | 0.740 |
Why?
|
| Time Factors | 10 | 2021 | 507 | 0.740 |
Why?
|
| Mobile Health Units | 1 | 2021 | 7 | 0.730 |
Why?
|
| Air Pollution, Indoor | 2 | 2021 | 13 | 0.730 |
Why?
|
| Molecular Diagnostic Techniques | 4 | 2020 | 132 | 0.720 |
Why?
|
| HLA Antigens | 2 | 2022 | 50 | 0.710 |
Why?
|
| Health Services Accessibility | 7 | 2019 | 280 | 0.710 |
Why?
|
| Condoms | 3 | 2011 | 88 | 0.690 |
Why?
|
| Penis | 2 | 2019 | 8 | 0.660 |
Why?
|
| Follow-Up Studies | 10 | 2021 | 370 | 0.660 |
Why?
|
| Heterosexuality | 2 | 2021 | 30 | 0.650 |
Why?
|
| Smoking | 7 | 2023 | 100 | 0.640 |
Why?
|
| Logistic Models | 9 | 2018 | 254 | 0.640 |
Why?
|
| Antibiotics, Antitubercular | 5 | 2021 | 47 | 0.640 |
Why?
|
| Cost of Illness | 4 | 2020 | 167 | 0.630 |
Why?
|
| Benzoxazines | 2 | 2017 | 123 | 0.630 |
Why?
|
| Urban Population | 6 | 2021 | 257 | 0.620 |
Why?
|
| Pain | 2 | 2018 | 41 | 0.620 |
Why?
|
| Retrospective Studies | 10 | 2023 | 799 | 0.600 |
Why?
|
| Socioeconomic Factors | 7 | 2019 | 411 | 0.590 |
Why?
|
| Medication Adherence | 4 | 2020 | 151 | 0.590 |
Why?
|
| Sexual Partners | 5 | 2021 | 215 | 0.590 |
Why?
|
| Radiography | 2 | 2023 | 80 | 0.580 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2017 | 5 | 0.560 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2017 | 5 | 0.560 |
Why?
|
| Urban Health | 3 | 2021 | 78 | 0.550 |
Why?
|
| Ataxia | 1 | 2017 | 4 | 0.550 |
Why?
|
| Intention | 2 | 2023 | 23 | 0.550 |
Why?
|
| Brain Diseases | 1 | 2017 | 24 | 0.540 |
Why?
|
| Wound Healing | 2 | 2016 | 29 | 0.540 |
Why?
|
| Hepatitis B | 3 | 2014 | 125 | 0.540 |
Why?
|
| Pleural Cavity | 1 | 2017 | 7 | 0.540 |
Why?
|
| Linear Models | 4 | 2023 | 83 | 0.530 |
Why?
|
| Lamivudine | 3 | 2017 | 89 | 0.530 |
Why?
|
| Cost-Benefit Analysis | 10 | 2019 | 253 | 0.530 |
Why?
|
| Rural Health Services | 2 | 2015 | 48 | 0.530 |
Why?
|
| Diabetic Foot | 1 | 2016 | 1 | 0.520 |
Why?
|
| Skin, Artificial | 1 | 2016 | 1 | 0.520 |
Why?
|
| Medicare | 1 | 2016 | 9 | 0.520 |
Why?
|
| Precancerous Conditions | 2 | 2014 | 10 | 0.520 |
Why?
|
| Cause of Death | 7 | 2017 | 221 | 0.510 |
Why?
|
| Genital Diseases, Male | 1 | 2016 | 8 | 0.510 |
Why?
|
| Disease Progression | 9 | 2019 | 154 | 0.500 |
Why?
|
| Respiratory Syncytial Virus Infections | 3 | 2024 | 200 | 0.490 |
Why?
|
| Lipopolysaccharides | 3 | 2011 | 37 | 0.480 |
Why?
|
| Telemedicine | 3 | 2021 | 25 | 0.480 |
Why?
|
| Patient Preference | 3 | 2011 | 30 | 0.470 |
Why?
|
| Inservice Training | 1 | 2015 | 7 | 0.470 |
Why?
|
| Allied Health Personnel | 1 | 2015 | 6 | 0.470 |
Why?
|
| Autopsy | 6 | 2023 | 140 | 0.470 |
Why?
|
| Politics | 1 | 2015 | 24 | 0.460 |
Why?
|
| Pilot Projects | 5 | 2024 | 179 | 0.460 |
Why?
|
| Disease Outbreaks | 3 | 2018 | 111 | 0.460 |
Why?
|
| Risk-Taking | 3 | 2012 | 121 | 0.460 |
Why?
|
| Caregivers | 1 | 2015 | 76 | 0.450 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 2 | 2014 | 19 | 0.450 |
Why?
|
| Diagnostic Tests, Routine | 5 | 2021 | 59 | 0.440 |
Why?
|
| Product Packaging | 1 | 2014 | 2 | 0.440 |
Why?
|
| Crime | 1 | 2014 | 3 | 0.440 |
Why?
|
| Zidovudine | 3 | 2018 | 59 | 0.440 |
Why?
|
| Inpatients | 4 | 2019 | 30 | 0.440 |
Why?
|
| Calcitriol | 1 | 2014 | 6 | 0.440 |
Why?
|
| Dermatologic Agents | 1 | 2014 | 6 | 0.440 |
Why?
|
| Tobacco Products | 1 | 2014 | 8 | 0.440 |
Why?
|
| Zinc Sulfate | 1 | 2014 | 6 | 0.440 |
Why?
|
| Commerce | 1 | 2014 | 22 | 0.440 |
Why?
|
| HIV Long-Term Survivors | 1 | 2014 | 8 | 0.430 |
Why?
|
| Patient Discharge | 4 | 2024 | 27 | 0.430 |
Why?
|
| Health Services Needs and Demand | 2 | 2012 | 57 | 0.430 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 2 | 2011 | 20 | 0.420 |
Why?
|
| Polymerase Chain Reaction | 5 | 2021 | 260 | 0.420 |
Why?
|
| Delayed Diagnosis | 1 | 2013 | 17 | 0.420 |
Why?
|
| Comorbidity | 5 | 2021 | 188 | 0.410 |
Why?
|
| Time-to-Treatment | 1 | 2013 | 42 | 0.410 |
Why?
|
| Floxacillin | 1 | 2013 | 6 | 0.410 |
Why?
|
| Bacillus | 2 | 2023 | 7 | 0.410 |
Why?
|
| Health Care Costs | 5 | 2019 | 115 | 0.410 |
Why?
|
| Urine | 2 | 2010 | 6 | 0.410 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 13 | 0.400 |
Why?
|
| Directly Observed Therapy | 2 | 2017 | 6 | 0.400 |
Why?
|
| Risk | 4 | 2019 | 87 | 0.400 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2024 | 48 | 0.400 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2023 | 34 | 0.390 |
Why?
|
| Pregnant Women | 4 | 2021 | 89 | 0.390 |
Why?
|
| Reverse Transcriptase Inhibitors | 3 | 2011 | 118 | 0.390 |
Why?
|
| Deoxycytidine | 1 | 2012 | 12 | 0.390 |
Why?
|
| Tenofovir | 4 | 2024 | 171 | 0.390 |
Why?
|
| Antigens, CD | 2 | 2024 | 26 | 0.390 |
Why?
|
| Emtricitabine | 4 | 2023 | 78 | 0.380 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2019 | 151 | 0.380 |
Why?
|
| Hepatitis C | 1 | 2012 | 37 | 0.380 |
Why?
|
| Sex Workers | 4 | 2022 | 116 | 0.380 |
Why?
|
| Counseling | 7 | 2024 | 143 | 0.380 |
Why?
|
| Organophosphonates | 1 | 2012 | 45 | 0.380 |
Why?
|
| Motivation | 3 | 2023 | 59 | 0.370 |
Why?
|
| Consumer Behavior | 1 | 2012 | 20 | 0.370 |
Why?
|
| Family | 1 | 2012 | 35 | 0.370 |
Why?
|
| Adenine | 1 | 2012 | 91 | 0.370 |
Why?
|
| Community Health Services | 1 | 2012 | 58 | 0.360 |
Why?
|
| Genetic Variation | 7 | 2024 | 175 | 0.360 |
Why?
|
| Biostatistics | 1 | 2011 | 4 | 0.350 |
Why?
|
| RNA, Viral | 8 | 2019 | 303 | 0.350 |
Why?
|
| Longitudinal Studies | 6 | 2023 | 435 | 0.350 |
Why?
|
| Smoking Prevention | 1 | 2011 | 5 | 0.350 |
Why?
|
| Activities of Daily Living | 1 | 2011 | 41 | 0.350 |
Why?
|
| Respiratory Syncytial Virus, Human | 2 | 2024 | 155 | 0.340 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 293 | 0.340 |
Why?
|
| Referral and Consultation | 1 | 2010 | 57 | 0.340 |
Why?
|
| Genotype | 8 | 2020 | 442 | 0.340 |
Why?
|
| Sequence Analysis, DNA | 6 | 2019 | 181 | 0.340 |
Why?
|
| Thinness | 1 | 2010 | 18 | 0.330 |
Why?
|
| Health Behavior | 1 | 2011 | 79 | 0.330 |
Why?
|
| Continuity of Patient Care | 3 | 2019 | 33 | 0.320 |
Why?
|
| Body Mass Index | 2 | 2014 | 321 | 0.320 |
Why?
|
| Lymphoma, AIDS-Related | 2 | 2021 | 16 | 0.310 |
Why?
|
| Tuberculosis Vaccines | 2 | 2019 | 8 | 0.310 |
Why?
|
| Choice Behavior | 1 | 2009 | 16 | 0.310 |
Why?
|
| Influenza Vaccines | 2 | 2025 | 144 | 0.310 |
Why?
|
| Funeral Homes | 2 | 2019 | 6 | 0.310 |
Why?
|
| Urban Health Services | 1 | 2009 | 10 | 0.310 |
Why?
|
| Health Expenditures | 2 | 2019 | 39 | 0.300 |
Why?
|
| Sexually Transmitted Diseases | 4 | 2021 | 103 | 0.300 |
Why?
|
| Receptors, IgG | 2 | 2019 | 28 | 0.300 |
Why?
|
| Viremia | 3 | 2019 | 66 | 0.300 |
Why?
|
| Microscopy | 3 | 2021 | 21 | 0.300 |
Why?
|
| Laboratories | 3 | 2021 | 47 | 0.300 |
Why?
|
| Reproductive Medicine | 1 | 2008 | 4 | 0.290 |
Why?
|
| Evolution, Molecular | 2 | 2024 | 60 | 0.290 |
Why?
|
| Communicable Diseases | 2 | 2018 | 62 | 0.280 |
Why?
|
| Pandemics | 4 | 2023 | 296 | 0.280 |
Why?
|
| Patient Compliance | 3 | 2017 | 120 | 0.280 |
Why?
|
| Biomarkers | 5 | 2022 | 327 | 0.270 |
Why?
|
| Health Personnel | 5 | 2020 | 231 | 0.270 |
Why?
|
| Delivery of Health Care | 3 | 2018 | 239 | 0.270 |
Why?
|
| Alleles | 5 | 2020 | 143 | 0.270 |
Why?
|
| Health Resources | 2 | 2012 | 66 | 0.270 |
Why?
|
| Receptors, CCR5 | 2 | 2019 | 54 | 0.270 |
Why?
|
| Africa | 6 | 2019 | 376 | 0.270 |
Why?
|
| Proportional Hazards Models | 5 | 2019 | 163 | 0.260 |
Why?
|
| Linezolid | 2 | 2024 | 22 | 0.260 |
Why?
|
| Killer Cells, Natural | 2 | 2024 | 52 | 0.260 |
Why?
|
| Computers, Handheld | 1 | 2006 | 2 | 0.260 |
Why?
|
| Geographic Information Systems | 1 | 2006 | 6 | 0.260 |
Why?
|
| Receptors, Virus | 2 | 2017 | 5 | 0.260 |
Why?
|
| Intraoperative Complications | 1 | 2006 | 8 | 0.250 |
Why?
|
| Disease Susceptibility | 3 | 2022 | 46 | 0.250 |
Why?
|
| Bacterial Infections | 2 | 2019 | 54 | 0.250 |
Why?
|
| Pneumonia | 1 | 2007 | 131 | 0.250 |
Why?
|
| Postpartum Period | 4 | 2019 | 85 | 0.240 |
Why?
|
| Age Factors | 5 | 2019 | 370 | 0.240 |
Why?
|
| Epidemiologic Methods | 3 | 2010 | 25 | 0.240 |
Why?
|
| Asymptomatic Infections | 2 | 2025 | 34 | 0.230 |
Why?
|
| Tight Junctions | 1 | 2024 | 2 | 0.230 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2024 | 3 | 0.230 |
Why?
|
| Lectins, C-Type | 1 | 2024 | 4 | 0.230 |
Why?
|
| Population Surveillance | 1 | 2006 | 325 | 0.230 |
Why?
|
| Attitude to Health | 2 | 2018 | 56 | 0.220 |
Why?
|
| Reproducibility of Results | 4 | 2020 | 217 | 0.220 |
Why?
|
| Cycloserine | 1 | 2024 | 2 | 0.220 |
Why?
|
| House Calls | 1 | 2024 | 9 | 0.220 |
Why?
|
| Clofazimine | 1 | 2024 | 8 | 0.220 |
Why?
|
| Hospital Mortality | 2 | 2019 | 95 | 0.220 |
Why?
|
| Kynurenine | 2 | 2021 | 7 | 0.220 |
Why?
|
| Drug Interactions | 1 | 2024 | 31 | 0.220 |
Why?
|
| Tryptophan | 2 | 2021 | 8 | 0.220 |
Why?
|
| Case-Control Studies | 7 | 2022 | 480 | 0.220 |
Why?
|
| Mutation | 5 | 2024 | 306 | 0.210 |
Why?
|
| Specimen Handling | 3 | 2020 | 105 | 0.210 |
Why?
|
| Housing | 2 | 2021 | 24 | 0.210 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2024 | 100 | 0.210 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2024 | 101 | 0.210 |
Why?
|
| Uganda | 5 | 2024 | 197 | 0.210 |
Why?
|
| Tertiary Care Centers | 2 | 2021 | 80 | 0.210 |
Why?
|
| Lung Diseases | 1 | 2023 | 29 | 0.210 |
Why?
|
| Attitude of Health Personnel | 2 | 2018 | 106 | 0.200 |
Why?
|
| Nicotine | 1 | 2023 | 12 | 0.200 |
Why?
|
| DNA, Viral | 2 | 2020 | 165 | 0.200 |
Why?
|
| Epidemics | 1 | 2023 | 65 | 0.200 |
Why?
|
| Contraceptive Agents | 1 | 2022 | 27 | 0.200 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2024 | 244 | 0.200 |
Why?
|
| Sexual and Gender Minorities | 1 | 2022 | 29 | 0.200 |
Why?
|
| Multivariate Analysis | 3 | 2013 | 171 | 0.190 |
Why?
|
| Qualitative Research | 3 | 2021 | 321 | 0.190 |
Why?
|
| Whooping Cough | 1 | 2023 | 36 | 0.190 |
Why?
|
| Chemokine CCL4 | 1 | 2022 | 14 | 0.190 |
Why?
|
| Hospitals, Teaching | 2 | 2020 | 21 | 0.190 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2022 | 21 | 0.190 |
Why?
|
| Prognosis | 4 | 2016 | 199 | 0.190 |
Why?
|
| Monte Carlo Method | 2 | 2013 | 11 | 0.190 |
Why?
|
| Anemia | 1 | 2022 | 41 | 0.190 |
Why?
|
| Vaccination | 3 | 2025 | 365 | 0.190 |
Why?
|
| Rural Health | 2 | 2021 | 118 | 0.190 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 150 | 0.190 |
Why?
|
| Physical Abuse | 1 | 2022 | 8 | 0.190 |
Why?
|
| Mortality | 2 | 2020 | 104 | 0.190 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2021 | 3 | 0.190 |
Why?
|
| Sex Offenses | 1 | 2022 | 29 | 0.190 |
Why?
|
| Substance-Related Disorders | 1 | 2022 | 51 | 0.180 |
Why?
|
| Developing Countries | 3 | 2018 | 400 | 0.180 |
Why?
|
| Influenza A virus | 2 | 2019 | 28 | 0.180 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2021 | 4 | 0.180 |
Why?
|
| Health Facilities | 2 | 2018 | 40 | 0.180 |
Why?
|
| Seroepidemiologic Studies | 4 | 2023 | 109 | 0.180 |
Why?
|
| Nucleic Acids | 1 | 2021 | 7 | 0.180 |
Why?
|
| Serologic Tests | 2 | 2019 | 26 | 0.180 |
Why?
|
| Hospitals | 3 | 2023 | 103 | 0.180 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 6 | 0.180 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2021 | 2 | 0.180 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2021 | 4 | 0.180 |
Why?
|
| United States | 2 | 2023 | 132 | 0.180 |
Why?
|
| Intensive Care Units | 1 | 2021 | 66 | 0.180 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2021 | 35 | 0.170 |
Why?
|
| Lipid Metabolism | 1 | 2021 | 44 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2024 | 106 | 0.170 |
Why?
|
| Health Promotion | 3 | 2020 | 109 | 0.170 |
Why?
|
| Liver | 3 | 2016 | 74 | 0.170 |
Why?
|
| Biological Assay | 1 | 2020 | 32 | 0.170 |
Why?
|
| Child, Hospitalized | 2 | 2021 | 26 | 0.170 |
Why?
|
| Ethambutol | 1 | 2020 | 9 | 0.170 |
Why?
|
| Pyrazinamide | 1 | 2020 | 14 | 0.160 |
Why?
|
| Feasibility Studies | 4 | 2021 | 101 | 0.160 |
Why?
|
| Alkynes | 2 | 2017 | 117 | 0.160 |
Why?
|
| Langerhans Cells | 1 | 2019 | 3 | 0.160 |
Why?
|
| Chemokine CCL27 | 1 | 2019 | 3 | 0.160 |
Why?
|
| Cyclopropanes | 2 | 2017 | 123 | 0.160 |
Why?
|
| Pregnancy Outcome | 1 | 2020 | 117 | 0.160 |
Why?
|
| Morbidity | 1 | 2019 | 37 | 0.160 |
Why?
|
| DNA, Bacterial | 2 | 2016 | 53 | 0.160 |
Why?
|
| Pharmacogenomic Variants | 1 | 2019 | 6 | 0.160 |
Why?
|
| Urinary Tract | 1 | 2019 | 4 | 0.160 |
Why?
|
| Medical Waste Disposal | 1 | 2019 | 3 | 0.160 |
Why?
|
| Safety Management | 1 | 2019 | 4 | 0.160 |
Why?
|
| Standard of Care | 1 | 2019 | 30 | 0.160 |
Why?
|
| Vaginal Smears | 2 | 2011 | 34 | 0.160 |
Why?
|
| Amputation, Traumatic | 1 | 2019 | 2 | 0.160 |
Why?
|
| Pneumococcal Infections | 1 | 2023 | 299 | 0.160 |
Why?
|
| Tobacco, Smokeless | 1 | 2019 | 7 | 0.160 |
Why?
|
| Bacteremia | 1 | 2020 | 79 | 0.160 |
Why?
|
| Patient Readmission | 1 | 2019 | 6 | 0.160 |
Why?
|
| Personal Protective Equipment | 1 | 2019 | 16 | 0.160 |
Why?
|
| Peripartum Period | 1 | 2019 | 9 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 1 | 2019 | 44 | 0.160 |
Why?
|
| Tobacco Use | 1 | 2019 | 12 | 0.160 |
Why?
|
| Self Care | 1 | 2019 | 14 | 0.160 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2019 | 7 | 0.160 |
Why?
|
| Postoperative Complications | 1 | 2019 | 34 | 0.160 |
Why?
|
| 3' Untranslated Regions | 1 | 2019 | 9 | 0.160 |
Why?
|
| Pain Measurement | 2 | 2016 | 15 | 0.150 |
Why?
|
| Mortuary Practice | 1 | 2019 | 3 | 0.150 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2019 | 103 | 0.150 |
Why?
|
| Clinical Trials as Topic | 3 | 2021 | 112 | 0.150 |
Why?
|
| Phylogeny | 3 | 2024 | 231 | 0.150 |
Why?
|
| Acute Disease | 1 | 2018 | 105 | 0.150 |
Why?
|
| Smokers | 1 | 2018 | 3 | 0.150 |
Why?
|
| Virus Shedding | 1 | 2018 | 24 | 0.150 |
Why?
|
| Random Allocation | 1 | 2018 | 23 | 0.150 |
Why?
|
| Poverty | 1 | 2019 | 152 | 0.150 |
Why?
|
| Interferon-gamma Release Tests | 3 | 2024 | 8 | 0.150 |
Why?
|
| Orthomyxoviridae | 1 | 2018 | 33 | 0.150 |
Why?
|
| Treatment Refusal | 2 | 2016 | 13 | 0.150 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2018 | 13 | 0.150 |
Why?
|
| Occupational Diseases | 1 | 2019 | 40 | 0.150 |
Why?
|
| Research | 1 | 2019 | 65 | 0.150 |
Why?
|
| Resins, Synthetic | 1 | 2018 | 3 | 0.150 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 8 | 0.140 |
Why?
|
| Analgesia | 1 | 2018 | 8 | 0.140 |
Why?
|
| Pain Management | 1 | 2018 | 12 | 0.140 |
Why?
|
| Pathology, Clinical | 1 | 2018 | 1 | 0.140 |
Why?
|
| Clinical Laboratory Services | 1 | 2018 | 4 | 0.140 |
Why?
|
| Research Design | 2 | 2021 | 124 | 0.140 |
Why?
|
| Kerosene | 1 | 2017 | 4 | 0.140 |
Why?
|
| Self Administration | 1 | 2017 | 5 | 0.140 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 4 | 0.140 |
Why?
|
| Antigens, Bacterial | 2 | 2023 | 32 | 0.140 |
Why?
|
| Diarrhea | 1 | 2018 | 76 | 0.140 |
Why?
|
| Interferon-gamma | 2 | 2023 | 39 | 0.140 |
Why?
|
| Zimbabwe | 3 | 2023 | 120 | 0.140 |
Why?
|
| Survival Analysis | 3 | 2016 | 149 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2018 | 49 | 0.140 |
Why?
|
| Directive Counseling | 1 | 2017 | 15 | 0.140 |
Why?
|
| Infant Mortality | 1 | 2018 | 97 | 0.140 |
Why?
|
| Receptors, Chemokine | 1 | 2017 | 6 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 125 | 0.130 |
Why?
|
| Environmental Exposure | 1 | 2017 | 45 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2020 | 198 | 0.130 |
Why?
|
| GTPase-Activating Proteins | 1 | 2017 | 3 | 0.130 |
Why?
|
| Selection, Genetic | 2 | 2007 | 31 | 0.130 |
Why?
|
| Disease Resistance | 1 | 2017 | 6 | 0.130 |
Why?
|
| Point-of-Care Testing | 1 | 2017 | 71 | 0.130 |
Why?
|
| Azides | 1 | 2016 | 1 | 0.130 |
Why?
|
| Propidium | 1 | 2016 | 1 | 0.130 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2014 | 187 | 0.130 |
Why?
|
| Acute Kidney Injury | 1 | 2016 | 15 | 0.130 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2016 | 17 | 0.130 |
Why?
|
| Double-Blind Method | 3 | 2024 | 272 | 0.130 |
Why?
|
| DNA Primers | 3 | 2012 | 55 | 0.130 |
Why?
|
| Odds Ratio | 2 | 2013 | 133 | 0.130 |
Why?
|
| Tissue Engineering | 1 | 2016 | 52 | 0.120 |
Why?
|
| Direct Service Costs | 1 | 2015 | 3 | 0.120 |
Why?
|
| Seasons | 3 | 2023 | 154 | 0.120 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2015 | 3 | 0.120 |
Why?
|
| Self Report | 3 | 2023 | 114 | 0.120 |
Why?
|
| Phenotype | 2 | 2014 | 158 | 0.120 |
Why?
|
| Child Welfare | 2 | 2009 | 16 | 0.120 |
Why?
|
| Lymphocyte Activation | 1 | 2015 | 40 | 0.120 |
Why?
|
| Drug Combinations | 2 | 2012 | 42 | 0.120 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 17 | 0.120 |
Why?
|
| Ambulatory Care | 2 | 2018 | 54 | 0.120 |
Why?
|
| Drug Design | 1 | 2015 | 29 | 0.120 |
Why?
|
| Quality Control | 1 | 2015 | 27 | 0.120 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 65 | 0.120 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 14 | 0.120 |
Why?
|
| Automation, Laboratory | 1 | 2015 | 13 | 0.120 |
Why?
|
| Fatty Liver | 1 | 2015 | 8 | 0.120 |
Why?
|
| Schools | 1 | 2015 | 73 | 0.120 |
Why?
|
| Interviews as Topic | 2 | 2018 | 203 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 146 | 0.110 |
Why?
|
| Reagent Kits, Diagnostic | 2 | 2011 | 56 | 0.110 |
Why?
|
| Papillomavirus Infections | 2 | 2012 | 74 | 0.110 |
Why?
|
| Administration, Cutaneous | 1 | 2014 | 31 | 0.110 |
Why?
|
| HIV Seronegativity | 2 | 2019 | 52 | 0.110 |
Why?
|
| Cities | 1 | 2014 | 37 | 0.110 |
Why?
|
| Cervix Uteri | 1 | 2014 | 22 | 0.110 |
Why?
|
| Gene Frequency | 4 | 2020 | 122 | 0.110 |
Why?
|
| Firmicutes | 2 | 2023 | 7 | 0.100 |
Why?
|
| Wounds and Injuries | 2 | 2019 | 26 | 0.100 |
Why?
|
| AIDS Vaccines | 2 | 2018 | 152 | 0.100 |
Why?
|
| Administration, Oral | 1 | 2013 | 127 | 0.100 |
Why?
|
| Sex Factors | 2 | 2014 | 227 | 0.100 |
Why?
|
| Analysis of Variance | 1 | 2012 | 64 | 0.100 |
Why?
|
| Alphapapillomavirus | 1 | 2012 | 8 | 0.100 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2012 | 33 | 0.100 |
Why?
|
| Asymptomatic Diseases | 1 | 2012 | 7 | 0.100 |
Why?
|
| Zambia | 3 | 2018 | 115 | 0.090 |
Why?
|
| Safe Sex | 1 | 2012 | 68 | 0.090 |
Why?
|
| Self Disclosure | 1 | 2012 | 8 | 0.090 |
Why?
|
| Pain, Postoperative | 1 | 2012 | 6 | 0.090 |
Why?
|
| Reagent Strips | 1 | 2011 | 2 | 0.090 |
Why?
|
| Focus Groups | 2 | 2010 | 196 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 22 | 0.090 |
Why?
|
| Cytokines | 2 | 2023 | 107 | 0.090 |
Why?
|
| Likelihood Functions | 1 | 2011 | 3 | 0.090 |
Why?
|
| Least-Squares Analysis | 1 | 2011 | 5 | 0.090 |
Why?
|
| Infection Control | 1 | 2011 | 31 | 0.090 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2011 | 37 | 0.090 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2011 | 5 | 0.090 |
Why?
|
| Nicotinic Agonists | 1 | 2011 | 1 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 45 | 0.090 |
Why?
|
| Models, Biological | 2 | 2008 | 77 | 0.090 |
Why?
|
| Health Surveys | 1 | 2010 | 59 | 0.090 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2011 | 135 | 0.080 |
Why?
|
| AIDS Serodiagnosis | 1 | 2011 | 44 | 0.080 |
Why?
|
| Menstruation Disturbances | 1 | 2010 | 7 | 0.080 |
Why?
|
| Prenatal Care | 1 | 2011 | 147 | 0.080 |
Why?
|
| Menstruation | 1 | 2010 | 10 | 0.080 |
Why?
|
| Contraception Behavior | 1 | 2010 | 54 | 0.080 |
Why?
|
| Quality of Life | 1 | 2011 | 177 | 0.080 |
Why?
|
| Blood | 1 | 2009 | 51 | 0.080 |
Why?
|
| Mozambique | 2 | 2021 | 55 | 0.080 |
Why?
|
| Maternal Welfare | 1 | 2009 | 9 | 0.080 |
Why?
|
| Quality of Health Care | 1 | 2009 | 62 | 0.080 |
Why?
|
| Poverty Areas | 1 | 2009 | 20 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2018 | 20 | 0.080 |
Why?
|
| Program Development | 1 | 2009 | 32 | 0.080 |
Why?
|
| Early Diagnosis | 2 | 2022 | 82 | 0.080 |
Why?
|
| Bone Marrow | 2 | 2022 | 19 | 0.070 |
Why?
|
| Linkage Disequilibrium | 2 | 2020 | 40 | 0.070 |
Why?
|
| Colposcopy | 1 | 2008 | 17 | 0.070 |
Why?
|
| Gene Expression Regulation | 2 | 2019 | 40 | 0.070 |
Why?
|
| Papanicolaou Test | 1 | 2008 | 29 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2008 | 133 | 0.070 |
Why?
|
| Microbial Viability | 2 | 2019 | 11 | 0.070 |
Why?
|
| Reference Values | 1 | 2007 | 64 | 0.070 |
Why?
|
| Cytomegalovirus | 1 | 2007 | 24 | 0.070 |
Why?
|
| Haplotypes | 2 | 2019 | 125 | 0.070 |
Why?
|
| Cytomegalovirus Infections | 1 | 2007 | 23 | 0.070 |
Why?
|
| Cote d'Ivoire | 1 | 2007 | 6 | 0.070 |
Why?
|
| Plasma | 2 | 2019 | 39 | 0.070 |
Why?
|
| Sequence Homology | 1 | 2007 | 11 | 0.070 |
Why?
|
| Models, Genetic | 1 | 2007 | 13 | 0.070 |
Why?
|
| Family Health | 2 | 2018 | 16 | 0.070 |
Why?
|
| Amino Acid Substitution | 1 | 2007 | 35 | 0.070 |
Why?
|
| Rwanda | 2 | 2018 | 30 | 0.070 |
Why?
|
| Obesity | 1 | 2010 | 367 | 0.070 |
Why?
|
| Africa South of the Sahara | 2 | 2023 | 353 | 0.070 |
Why?
|
| Kenya | 2 | 2018 | 183 | 0.060 |
Why?
|
| Drug Resistance, Microbial | 1 | 2006 | 26 | 0.060 |
Why?
|
| Mothers | 2 | 2018 | 195 | 0.060 |
Why?
|
| Disease Transmission, Infectious | 2 | 2019 | 39 | 0.060 |
Why?
|
| Polymorphism, Genetic | 2 | 2020 | 99 | 0.060 |
Why?
|
| Vietnam | 1 | 2024 | 13 | 0.060 |
Why?
|
| Cotinine | 1 | 2024 | 7 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2025 | 55 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2024 | 67 | 0.060 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2016 | 90 | 0.050 |
Why?
|
| Genome, Viral | 1 | 2024 | 64 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2016 | 175 | 0.050 |
Why?
|
| Liver Cirrhosis | 2 | 2015 | 28 | 0.050 |
Why?
|
| Mucous Membrane | 1 | 2023 | 12 | 0.050 |
Why?
|
| Cough | 1 | 2023 | 14 | 0.050 |
Why?
|
| Ibuprofen | 1 | 2023 | 3 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2023 | 10 | 0.050 |
Why?
|
| Claudin-1 | 1 | 2023 | 2 | 0.050 |
Why?
|
| Aspirin | 1 | 2023 | 15 | 0.050 |
Why?
|
| Travel | 1 | 2023 | 21 | 0.050 |
Why?
|
| Computer Simulation | 3 | 2009 | 56 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2023 | 39 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 60 | 0.050 |
Why?
|
| Network Meta-Analysis | 1 | 2023 | 8 | 0.050 |
Why?
|
| Methyltransferases | 1 | 2022 | 2 | 0.050 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2022 | 2 | 0.050 |
Why?
|
| Ion Channels | 1 | 2022 | 3 | 0.050 |
Why?
|
| Decision Support Techniques | 2 | 2017 | 7 | 0.050 |
Why?
|
| Bordetella pertussis | 1 | 2023 | 29 | 0.050 |
Why?
|
| World Health Organization | 1 | 2023 | 137 | 0.050 |
Why?
|
| Receptors, Transferrin | 1 | 2022 | 6 | 0.050 |
Why?
|
| Ferritins | 1 | 2022 | 23 | 0.050 |
Why?
|
| Iron | 1 | 2022 | 32 | 0.050 |
Why?
|
| Proteomics | 1 | 2022 | 15 | 0.050 |
Why?
|
| Chemokine CCL3 | 1 | 2022 | 23 | 0.050 |
Why?
|
| Homosexuality, Male | 1 | 2022 | 52 | 0.050 |
Why?
|
| Carrier State | 1 | 2023 | 92 | 0.050 |
Why?
|
| Nasopharynx | 1 | 2023 | 151 | 0.050 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2022 | 25 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 4 | 0.050 |
Why?
|
| Genomics | 1 | 2022 | 109 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2022 | 49 | 0.050 |
Why?
|
| Diarylquinolines | 1 | 2022 | 39 | 0.050 |
Why?
|
| Gene Rearrangement | 1 | 2021 | 15 | 0.050 |
Why?
|
| Ethiopia | 1 | 2021 | 18 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2022 | 106 | 0.050 |
Why?
|
| Tongue | 1 | 2021 | 5 | 0.050 |
Why?
|
| Culture Media, Conditioned | 1 | 2021 | 4 | 0.050 |
Why?
|
| Models, Theoretical | 2 | 2012 | 80 | 0.050 |
Why?
|
| Shigella flexneri | 1 | 2001 | 1 | 0.040 |
Why?
|
| Dysentery, Bacillary | 1 | 2001 | 3 | 0.040 |
Why?
|
| Foodborne Diseases | 1 | 2001 | 6 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2021 | 26 | 0.040 |
Why?
|
| Immunoglobulins | 1 | 2021 | 11 | 0.040 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2021 | 4 | 0.040 |
Why?
|
| Cooking | 1 | 2021 | 7 | 0.040 |
Why?
|
| Animals | 2 | 2021 | 1081 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 24 | 0.040 |
Why?
|
| Algorithms | 1 | 2021 | 106 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2023 | 303 | 0.040 |
Why?
|
| Mycobacterium smegmatis | 1 | 2021 | 20 | 0.040 |
Why?
|
| International Cooperation | 1 | 2001 | 50 | 0.040 |
Why?
|
| Employment | 1 | 2021 | 27 | 0.040 |
Why?
|
| Sports | 1 | 2001 | 43 | 0.040 |
Why?
|
| Bacterial Proteins | 1 | 2021 | 119 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2020 | 5 | 0.040 |
Why?
|
| Streptococcus pneumoniae | 1 | 2023 | 336 | 0.040 |
Why?
|
| Life Expectancy | 2 | 2011 | 31 | 0.040 |
Why?
|
| South America | 1 | 2020 | 27 | 0.040 |
Why?
|
| Brazil | 1 | 2020 | 47 | 0.040 |
Why?
|
| Cell Movement | 1 | 2019 | 13 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 2019 | 20 | 0.040 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2019 | 29 | 0.040 |
Why?
|
| Waste Disposal Facilities | 1 | 2019 | 9 | 0.040 |
Why?
|
| Workload | 1 | 2019 | 13 | 0.040 |
Why?
|
| Income | 1 | 2019 | 85 | 0.040 |
Why?
|
| India | 1 | 2019 | 62 | 0.040 |
Why?
|
| Lymphocyte Subsets | 1 | 2019 | 6 | 0.040 |
Why?
|
| Immunogenetic Phenomena | 1 | 2019 | 7 | 0.040 |
Why?
|
| Mouthwashes | 1 | 2019 | 3 | 0.040 |
Why?
|
| Drinking Water | 1 | 2019 | 3 | 0.040 |
Why?
|
| Chlorhexidine | 1 | 2019 | 10 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2019 | 65 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 48 | 0.040 |
Why?
|
| Influenza B virus | 1 | 2019 | 42 | 0.040 |
Why?
|
| Human Genome Project | 1 | 2018 | 7 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 176 | 0.040 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2019 | 36 | 0.040 |
Why?
|
| Drug Costs | 1 | 2018 | 18 | 0.040 |
Why?
|
| Aftercare | 1 | 2018 | 10 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2019 | 89 | 0.040 |
Why?
|
| Volition | 1 | 2018 | 1 | 0.040 |
Why?
|
| Research Personnel | 1 | 2019 | 19 | 0.040 |
Why?
|
| Models, Econometric | 1 | 2018 | 3 | 0.040 |
Why?
|
| Elective Surgical Procedures | 1 | 2018 | 10 | 0.040 |
Why?
|
| Alcoholism | 1 | 2018 | 17 | 0.040 |
Why?
|
| Actinomycetales | 1 | 2018 | 2 | 0.040 |
Why?
|
| Trehalose | 1 | 2018 | 2 | 0.040 |
Why?
|
| Naphthalimides | 1 | 2018 | 2 | 0.040 |
Why?
|
| Molecular Probes | 1 | 2018 | 4 | 0.040 |
Why?
|
| Mycobacterium | 1 | 2018 | 16 | 0.040 |
Why?
|
| CD4 Antigens | 1 | 2018 | 49 | 0.040 |
Why?
|
| Infant, Low Birth Weight | 1 | 2018 | 35 | 0.040 |
Why?
|
| Gestational Age | 1 | 2018 | 80 | 0.040 |
Why?
|
| Reminder Systems | 1 | 2017 | 8 | 0.030 |
Why?
|
| Circulating Tumor DNA | 1 | 2017 | 2 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 468 | 0.030 |
Why?
|
| Health Plan Implementation | 1 | 2017 | 16 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 139 | 0.030 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2017 | 4 | 0.030 |
Why?
|
| Text Messaging | 1 | 2017 | 25 | 0.030 |
Why?
|
| Forms and Records Control | 1 | 1997 | 3 | 0.030 |
Why?
|
| Medical Records | 1 | 1997 | 23 | 0.030 |
Why?
|
| Pre-Eclampsia | 1 | 2018 | 56 | 0.030 |
Why?
|
| Receptors, CXCR6 | 1 | 2017 | 3 | 0.030 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2017 | 3 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2017 | 4 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2017 | 16 | 0.030 |
Why?
|
| Spleen | 1 | 2016 | 9 | 0.030 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2016 | 16 | 0.030 |
Why?
|
| Cryptococcosis | 1 | 2016 | 17 | 0.030 |
Why?
|
| Breast Feeding | 1 | 2017 | 120 | 0.030 |
Why?
|
| Perception | 1 | 2016 | 42 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2015 | 20 | 0.030 |
Why?
|
| Fetal Blood | 1 | 2015 | 27 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2015 | 19 | 0.030 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2016 | 198 | 0.030 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2015 | 31 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 10 | 0.030 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2015 | 54 | 0.030 |
Why?
|
| Granuloma | 1 | 2015 | 3 | 0.030 |
Why?
|
| Hypertension | 1 | 2019 | 419 | 0.030 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2015 | 12 | 0.030 |
Why?
|
| Health Policy | 1 | 2015 | 140 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2014 | 48 | 0.030 |
Why?
|
| Survival Rate | 1 | 2013 | 96 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2012 | 4 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 2012 | 10 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2012 | 13 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 38 | 0.020 |
Why?
|
| Length of Stay | 1 | 2012 | 43 | 0.020 |
Why?
|
| Skin | 1 | 2012 | 38 | 0.020 |
Why?
|
| Kidney | 1 | 2012 | 46 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 56 | 0.020 |
Why?
|
| United Kingdom | 1 | 2011 | 33 | 0.020 |
Why?
|
| Medical Audit | 1 | 2011 | 26 | 0.020 |
Why?
|
| Thailand | 1 | 2011 | 26 | 0.020 |
Why?
|
| Voluntary Programs | 1 | 2011 | 5 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 77 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2011 | 42 | 0.020 |
Why?
|
| Hepatitis B virus | 1 | 2012 | 157 | 0.020 |
Why?
|
| Social Stigma | 1 | 2011 | 80 | 0.020 |
Why?
|
| Amenorrhea | 1 | 2010 | 9 | 0.020 |
Why?
|
| Culture | 1 | 2010 | 23 | 0.020 |
Why?
|
| Consensus Sequence | 1 | 2009 | 4 | 0.020 |
Why?
|
| Decision Trees | 1 | 2009 | 3 | 0.020 |
Why?
|
| Herpes Genitalis | 1 | 2010 | 43 | 0.020 |
Why?
|
| Disease Reservoirs | 1 | 2009 | 1 | 0.020 |
Why?
|
| Virus Latency | 1 | 2009 | 5 | 0.020 |
Why?
|
| Contraceptive Agents, Female | 1 | 2010 | 47 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 2009 | 57 | 0.020 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2008 | 41 | 0.020 |
Why?
|
| Codon | 1 | 2007 | 7 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 263 | 0.020 |
Why?
|
| Pyrimidinones | 1 | 2006 | 24 | 0.020 |
Why?
|
| Lopinavir | 1 | 2006 | 137 | 0.020 |
Why?
|
| Ritonavir | 1 | 2006 | 137 | 0.020 |
Why?
|
| Viral Proteins | 1 | 2005 | 30 | 0.010 |
Why?
|
| Chickens | 1 | 2001 | 5 | 0.010 |
Why?
|
| Fruit | 1 | 2001 | 5 | 0.010 |
Why?
|
| Food Handling | 1 | 2001 | 5 | 0.010 |
Why?
|
| Zea mays | 1 | 2001 | 5 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2001 | 40 | 0.010 |
Why?
|
| Beverages | 1 | 2001 | 42 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2001 | 57 | 0.010 |
Why?
|